Cargando…

Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics

A frequent observation in several malignancies is the development of resistance to therapy that results in frequent tumor relapse and metastasis. Much of the tumor resistance phenotype comes from its heterogeneity that halts the ability of therapeutic agents to eliminate all cancer cells effectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Bighetti-Trevisan, Rayana L., Sousa, Lucas O., Castilho, Rogerio M., Almeida, Luciana O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874936/
https://www.ncbi.nlm.nih.gov/pubmed/31781251
http://dx.doi.org/10.1155/2019/9618065
_version_ 1783472917955215360
author Bighetti-Trevisan, Rayana L.
Sousa, Lucas O.
Castilho, Rogerio M.
Almeida, Luciana O.
author_facet Bighetti-Trevisan, Rayana L.
Sousa, Lucas O.
Castilho, Rogerio M.
Almeida, Luciana O.
author_sort Bighetti-Trevisan, Rayana L.
collection PubMed
description A frequent observation in several malignancies is the development of resistance to therapy that results in frequent tumor relapse and metastasis. Much of the tumor resistance phenotype comes from its heterogeneity that halts the ability of therapeutic agents to eliminate all cancer cells effectively. Tumor heterogeneity is, in part, controlled by cancer stem cells (CSC). CSC may be considered the reservoir of cancer cells as they exhibit properties of self-renewal and plasticity and the capability of reestablishing a heterogeneous tumor cell population. The endowed resistance mechanisms of CSC are mainly attributed to several factors including cellular quiescence, accumulation of ABC transporters, disruption of apoptosis, epigenetic reprogramming, and metabolism. There is a current need to develop new therapeutic drugs capable of targeting CSC to overcome tumor resistance. Emerging in vitro and in vivo studies strongly support the potential benefits of combination therapies capable of targeting cancer stem cell-targeting agents. Clinical trials are still underway to address the pharmacokinetics, safety, and efficacy of combination treatment. This review will address the main characteristics, therapeutic implications, and perspectives of targeting CSC to improve current anticancer therapeutics.
format Online
Article
Text
id pubmed-6874936
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-68749362019-11-28 Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics Bighetti-Trevisan, Rayana L. Sousa, Lucas O. Castilho, Rogerio M. Almeida, Luciana O. Stem Cells Int Review Article A frequent observation in several malignancies is the development of resistance to therapy that results in frequent tumor relapse and metastasis. Much of the tumor resistance phenotype comes from its heterogeneity that halts the ability of therapeutic agents to eliminate all cancer cells effectively. Tumor heterogeneity is, in part, controlled by cancer stem cells (CSC). CSC may be considered the reservoir of cancer cells as they exhibit properties of self-renewal and plasticity and the capability of reestablishing a heterogeneous tumor cell population. The endowed resistance mechanisms of CSC are mainly attributed to several factors including cellular quiescence, accumulation of ABC transporters, disruption of apoptosis, epigenetic reprogramming, and metabolism. There is a current need to develop new therapeutic drugs capable of targeting CSC to overcome tumor resistance. Emerging in vitro and in vivo studies strongly support the potential benefits of combination therapies capable of targeting cancer stem cell-targeting agents. Clinical trials are still underway to address the pharmacokinetics, safety, and efficacy of combination treatment. This review will address the main characteristics, therapeutic implications, and perspectives of targeting CSC to improve current anticancer therapeutics. Hindawi 2019-11-12 /pmc/articles/PMC6874936/ /pubmed/31781251 http://dx.doi.org/10.1155/2019/9618065 Text en Copyright © 2019 Rayana L. Bighetti-Trevisan et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Bighetti-Trevisan, Rayana L.
Sousa, Lucas O.
Castilho, Rogerio M.
Almeida, Luciana O.
Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics
title Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics
title_full Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics
title_fullStr Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics
title_full_unstemmed Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics
title_short Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics
title_sort cancer stem cells: powerful targets to improve current anticancer therapeutics
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874936/
https://www.ncbi.nlm.nih.gov/pubmed/31781251
http://dx.doi.org/10.1155/2019/9618065
work_keys_str_mv AT bighettitrevisanrayanal cancerstemcellspowerfultargetstoimprovecurrentanticancertherapeutics
AT sousalucaso cancerstemcellspowerfultargetstoimprovecurrentanticancertherapeutics
AT castilhorogeriom cancerstemcellspowerfultargetstoimprovecurrentanticancertherapeutics
AT almeidalucianao cancerstemcellspowerfultargetstoimprovecurrentanticancertherapeutics